Lenzing's Double-Edged Recovery: Profits Climb as Investors Brace for the August 25 Dilution Test

Lenzing's net profit doubles in H1 2026, yet shares slide on pending €600M capital raise and dilution concerns ahead of August 25 shareholder vote.

The arithmetic at Lenzing is getting harder to ignore. Europe's largest fibre maker more than doubled its net profit in the first half of 2026, yet its shares keep sliding — a disconnect that says less about the quality of the turnaround and more about the bill still coming due.

The numbers themselves tell a story of deliberate contraction. Revenue slipped from €1.34 billion to €1.27 billion in the six months to June 30, while EBITDA eased to €239.2 million from €268.6 million, dragging the margin down from 20 percent to 18.9 percent. Management attributes the top-line retreat to an intentional pullback from low-margin standard fibres and softer external pulp prices. Net profit, however, jumped to €35.6 million from €15.2 million — a doubling that executives point to as evidence that the strategy of selling less but earning more is taking hold.

A Market That's Not Yet Convinced

Investors have responded with a shrug that borders on skepticism. The stock slipped 2.1 percent on Thursday, dropping below its 50-day moving average of €24.53, and has now shed 5.7 percent over the past week. At €23.65, the shares sit roughly 21 percent below their 52-week high of €29.75 — a persistent discount that reflects the market's focus on what happens next rather than what has already been achieved.

That hesitation is quantifiable. The stock's 30-day volatility stands at 48 percent, with a relative strength index of 46.9, signalling a market that has yet to pick a direction. The technical picture mirrors the fundamental one: an operating recovery is visible in the numbers, but it is being overshadowed by the mechanics of a pending capital increase whose terms remain unknown.

The August 25 Reckoning

All eyes now turn to the extraordinary general meeting scheduled for August 25 at 10:00 a.m. in the Kulturzentrum Lenzing, where shareholders will vote on a capital package totaling €600 million. The centrepiece is a rights issue of up to €300 million, alongside separate financing arrangements of a similar size and the extension of existing debt maturities into 2030.

The dilution math is sobering for a company with a market capitalisation of roughly €898 million. A rights issue of this magnitude will meaningfully dilute existing holders unless they participate proportionally — and the share price's recent drift suggests the market has already begun pricing in that effect.

The vote, however, looks set to pass comfortably. The syndicate of B&C Group and Suzano, which controls 52.25 percent of the share capital, has irrevocably committed to subscribe up to €156.7 million. Oberbank AG, holding 3.86 percent, has pledged up to €11.6 million. An international banking consortium will underwrite any shares not taken up by existing shareholders.

Cutting Deep to Reshape the Business

The restructuring behind this capital ask is already underway. CEO Georg Kasperkovitz, who took the helm on June 1, has moved with unusual speed. In late July, the company announced the closure of its Heiligenkreuz fibre production site in Austria by the end of 2026, with the Grimsby plant in England to follow by the end of 2027. Around 2,000 jobs worldwide will disappear by 2027 under the strategy dubbed "Grow Nonwovens, Reset Textiles," which aims to pivot the business toward nonwovens — a segment the company plans to expand significantly by 2030.

The human and financial costs are substantial. Lenzing has begun searching for a buyer for Heiligenkreuz, a process the CEO expects to take several months. The provincial government of Burgenland, led by Governor Hans Peter Doskozil, is supporting the investor search and has not ruled out the province itself taking over the plant if no buyer emerges and closure becomes imminent. A separate sales process is underway for the Indonesian viscose site PT South Pacific Viscose.

The balance sheet will absorb the blow this year: the company expects impairment charges on property, plant and equipment of up to €150 million, plus restructuring provisions of up to €40 million for personnel measures. Management stresses that EBITDA will not be affected by these charges in 2026.

The Verdict Still Pending

Medium-term targets are ambitious: an EBITDA improvement of €150 million, a margin between 20 and 25 percent, and leverage below 2.5 times. Whether those goals are achievable — and whether the operational gains ultimately accrue to shareholders or evaporate in dilution — depends on the terms unveiled at the August 25 meeting.

For now, the market's verdict is a split decision. The operational story has substance, backed by hard numbers rather than promises. But until the rights issue's conditions are spelled out, investors are effectively buying a recovery narrative with an unknown price tag attached. The stock's 22 percent gap from its 52-week high suggests the market is waiting for clarity before committing — a patience that may prove rewarded or costly, depending on what the company reveals in two weeks' time.